StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
SLNBullishEarningsnews
High materiality9/10

Silence Therapeutics Q2 results highlight divesiran durability and 2027 INDs

Aug 10, 2026, 7:18 AM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The combination of SANRECO Phase 2 dosing completion with durable PV data, plus 2027 IND timelines for SLN365/SLN098 and AZN collaboration implications, provides multiple price-relevant catalysts within 6–12 months. Historically, biotech name-specific data readouts and strong collaboration news tend to drive multiple expansion and re-rating when cash burn improves and late-stage reads look favorable.

AI summary

What happened, with direct paths to the underlying reporting

Silence Therapeutics posted Q2 2026 results with progress across its divesiran program (SANRECO Phase 2 dosing completed in 48 PV patients) and the ANGPTL3 program SLN312 with AstraZeneca, plus IND timing for SLN365/SLN098 in 2027. Cash stood at $72.1 million; R&D fell to $9.1 million. Key catalysts—SANRECO durability data and 2027 INDs—could drive near-term upside over the next 6–12 months.

  • Phase 2 SANRECO divesiran dosing completed; 48 PV patients. EHA data show durable efficacy.
  • Divesiran data hints at best-in-class PV profile.
  • IND timing for SLN365 and SLN098 expected in 2027.
  • Cash and equivalents $72.1 million; Q2 net loss $12.3 million.
  • R&D expense down to $9.1 million; zerlasiran Phase 3 prep completed.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event